Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor

doi:10.3748/wjg.v30.i8.863

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2034)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

1098

Figures (1-7)

192

Tables (1-3)

149

Sum=1537

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

334

Sum=427

Feb 28, 2024 (publication date) through Oct 2, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Feb 28, 2024; 30(8): 863-880
Published online Feb 28, 2024. doi: 10.3748/wjg.v30.i8.863

Full Size Figure Download Figure

Figure 7 Nomogram for overall survival. A: Nomogram for overall survival (OS); B: One-year and 3-year area under the curves for OS; C: Calibration curves for OS; D: Decision curve analysis for OS. AUC: Area under the curve; OS: Overall survival; TP: Total protein; Eosi: Eosinophil count; CA724: Carbohydrate antigen 724; CA125: Carbohydrate antigen 125.

Citation: Deng GM, Song HB, Du ZZ, Xue YW, Song HJ, Li YZ. Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor. World J Gastroenterol 2024; 30(8): 863-880
URL: https://www.wjgnet.com/1007-9327/full/v30/i8/863.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i8.863